

Lung Cancer Therapeutics Market, 2012 to 2023

<https://marketpublishers.com/r/L541E0FA3CDEN.html>

Date: December 2017

Pages: 210

Price: US\$ 4,400.00 (Single User License)

ID: L541E0FA3CDEN

Abstracts

Global Lung Cancer Therapeutics Market

Lung cancer or lung carcinoma is the disease characterized by the abnormal proliferation of tumour cells in the lung tissues. Lung cancer is classified into 3 types namely lung carcinoid tumour, small cell lung cancer, and non-small cell lung cell cancer. Common symptoms associated with the lung cancer include a cough, weight loss, shortness of breath, and chest pains. Smoking and prolonged use of tobacco are the common risk factors for the lung cancer. Lung cancer can be diagnosed by the biopsy performed by using CT-guidance or bronchoscopy. Lung cancer can be treated by radiotherapy, chemotherapy, and surgery.

Increasing pollution owing to rapid industrialization, a rise in the number of tobacco consumption and smoking population, growing government funding for the R&D activities, and rise in demand for targeted therapies are anticipated to fuel the growth of lung cancer therapeutics market. Moreover, innovation of newer radiotherapies, a launch of low priced generic drugs, and rise in prevalence of non-small cell lung cancer are expected to propel the lung cancer therapeutics market over the forecast period. However, stringent regulatory policies, patent expiry of lung cancer therapeutics, poor cancer diagnostics in underdeveloped countries, and adverse effects associated with the treatment might hamper the growth of lung cancer therapeutics market.

Lung cancer therapeutics market segmented based on the treatment type, disease type, and end user

Based on the drug type, lung cancer therapeutics market segmented into the following:

Chemotherapy

Taxol

Navelbine

Alimta
Cisplatin
Camptosar
Others
Targeted therapy
Gilotrif
Tarceva
Avastin
Iressa
Others

Based on the disease type, lung cancer therapeutics market segmented into the following:

Small cell lung cancer
Non-small cell lung cancer
Large carcinoid tumour

Based on the end user, lung cancer therapeutics market segmented into the following:

Hospitals
Oncology Clinics
Ambulatory surgical centres

Global lung cancer therapeutics market is growing at a significant CAGR over the forecast timeframe owing to increase in the R&D activities clinical trials for the innovation of new drugs and vaccines for the treatment of lung cancer. Increase in the prevalence of lung cancer (according to world cancer research fund international 2012, lung cancer was the most common cancer which contributes 13% share of the new cancer cases diagnosed) also propelling the lung cancer therapeutics market. Acquisitions & mergers, collaborations are the key strategies adopted by the players to gain revenue growth in lung cancer therapeutics market. For instance, in November 2015, Eli Lilly and Co. and Merck & Co., Inc. collaborated to evaluate the efficacy and safety of a combination of the Alimta and Keytruda under phase III trials for the treatment of non-small cell lung cancer. Moreover, in January 2016, VisionGate acquired a patent from University of Colorado for Iloprost used in the treatment of lung cancer. Similarly, In September 2014, Asterias Biotherapeutics collaborated with Cancer Research UK for the development of a vaccine for the treatment of non-small

cell lung cancer.

Geographically, Lung cancer therapeutics market is segmented into the Europe, Latin America, Asia Pacific, Middle East and Africa, and North America. North America lung cancer therapeutics market is growing due to increase in the prevalence of lung cancer majorly in U.S. (according to CDC 2014, about 215,951 people diagnosed with lung cancer and 155,526 people died of the lung cancer). In addition, increase the funding for the R&D activities, and early diagnosis of the disease is expected to propel the lung cancer therapeutics market in North America. In Europe region, rise in the prevalence of lung cancer majorly in Hungary, Serbia, U.K and other Europe countries (according to Cancer Research UK, about 46,403 new lung cancer in the UK and 35,895 people died of the disease), rise in the government funding for lung cancer R&D activities, and advanced healthcare infrastructure are boosting the lung cancer therapeutics market. Asia Pacific region is exhibiting significant growth in lung cancer therapeutics market owing to rapid industrialization and availability of low-cost generic products in the region.

Some of the players in lung cancer therapeutics market are Eli Lilly and Company (U.S.), GlaxoSmithKline Plc (U.K.), AstraZeneca (U.S.), Pfizer, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co. Inc. (U.S.), Boehringer Ingelheim GmbH (Germany), Novartis AG (Switzerland), Takeda Pharmaceuticals Co. Ltd. (Japan), Abbvie, Inc. (U.S.), VisionGate, Inc. (U.S.), and Asterias Biotherapeutics (Biotime) (U.S.) to name a few.

In April 2017, Takeda Pharmaceutical received an approval from FDA for Alunbrig (brigatinib) used in the treatment of ALK+ non-small cell lung cancer

In April 2017, AstraZeneca received approval from European Commission for the marketing authorization of Tagrisso used in the treatment of non-small cell lung cancer

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL LUNG CANCER THERAPEUTICS MARKET INTRODUCTION

2.1. Global Lung Cancer Therapeutics Market – Taxonomy

2.2. Global Lung Cancer Therapeutics Market –Definitions

2.2.1. Drug class

2.2.2. Distribution Channel

3. GLOBAL LUNG CANCER THERAPEUTICS MARKET DYNAMICS

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Lung Cancer Therapeutics Market Dynamics – Factors Impact Analysis

3.6. Global Lung Cancer Therapeutics Market – Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

3.6.4. China

3.7. Global Lung Cancer Therapeutics Market – Pipeline Analysis

4. GLOBAL LUNG CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Drug Class Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

5.1.1. Chemotherapy

5.1.1.1. Taxol

- 5.1.1.2. Navelbine
- 5.1.1.3. Alimta
- 5.1.1.4. Cisplatin
- 5.1.1.5. Camptosar
- 5.1.1.6. Others
- 5.1.2. Targeted therapy
 - 5.1.2.1. Gilotrif
 - 5.1.2.2. Tarceva
 - 5.1.2.3. Avastin
 - 5.1.2.4. Iressa
 - 5.1.2.5. Others
- 5.1.3. Market Opportunity Analysis

6. GLOBAL LUNG CANCER THERAPEUTICS MARKET FORECAST, BY DISEASE TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

- 6.1. Small Cell Lung Cancer
 - 6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 6.1.3. Market Opportunity Analysis
- 6.2. Non-Small Cell Lung Cancer
 - 6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 6.2.3. Market Opportunity Analysis
- 6.3. Large Carcinoid Tumor
 - 6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7. MARKET OPPORTUNITY ANALYSIS GLOBAL LUNG CANCER THERAPEUTICS MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023

- 7.1. Hospitals
 - 7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 7.1.3. Market Opportunity Analysis
- 7.2. Oncology Clinics
 - 7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 7.2.3. Market Opportunity Analysis

7.3. Ambulatory Surgical Centers

- 7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 7.3.3. Market Opportunity Analysis

8. GLOBAL LUNG CANCER THERAPEUTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America

- 8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.1.3. Market Opportunity Analysis

8.2. Europe

- 8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.2.3. Market Opportunity Analysis

8.3. Asia-Pacific

- 8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.3.3. Market Opportunity Analysis

8.4. Latin America

- 8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.4.3. Market Opportunity Analysis

8.5. Middle East and Africa

- 8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.5.3. Market Opportunity Analysis

8.6. Global Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Class, Diseases Type, End User, and Region, 2017 – 2023

9. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

- 9.1.2. Chemotherapy
 - 9.1.2.1. Taxol
 - 9.1.2.2. Navelbine

- 9.1.2.3. Alimta
- 9.1.2.4. Cisplatin
- 9.1.2.5. Camptosar
- 9.1.2.6. Others
- 9.1.3. Targeted therapy
 - 9.1.3.1. Gilotrif
 - 9.1.3.2. Tarceva
 - 9.1.3.3. Avastin
 - 9.1.3.4. Iressa
 - 9.1.3.5. Others
- 9.1.4. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 9.1.4.1. Small cell lung cancer
 - 9.1.4.2. Non-small cell lung cancer
 - 9.1.4.3. Large carcinoid tumor
- 9.1.5. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 9.1.5.1. Hospitals
 - 9.1.5.2. Oncology Clinics
 - 9.1.5.3. Ambulatory Surgical Centers
- 9.1.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
 - 9.1.6.1. U.S.
 - 9.1.6.2. Canada
- 9.1.7. North America Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Class, Disease Type, End User and Country, 2017 – 2023
- 9.1.8. North America Lung Cancer Therapeutics Market Dynamics – Trends

10. EUROPE LUNG CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

- 10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
- 10.1.2. Chemotherapy
 - 10.1.2.1. Taxol
 - 10.1.2.2. Navelbine
 - 10.1.2.3. Alimta
 - 10.1.2.4. Cisplatin
 - 10.1.2.5. Camptosar

- 10.1.2.6. Others
- 10.1.3. Targeted therapy
 - 10.1.3.1. Gilotrif
 - 10.1.3.2. Tarceva
 - 10.1.3.3. Avastin
 - 10.1.3.4. Iressa
 - 10.1.3.5. Others
- 10.1.4. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 10.1.4.1. Small cell lung cancer
 - 10.1.4.2. Non-small cell lung cancer
 - 10.1.4.3. Large carcinoid tumor
- 10.1.5. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 10.1.5.1. Hospitals
 - 10.1.5.2. Oncology Clinics
 - 10.1.5.3. Ambulatory Surgical Centers
- 10.1.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 10.1.6.1. Germany
 - 10.1.6.2. UK
 - 10.1.6.3. France
 - 10.1.6.4. Spain
 - 10.1.6.5. Italy
 - 10.1.6.6. Russia
 - 10.1.6.7. Poland
 - 10.1.6.8. Rest of Europe
- 10.1.7. Europe Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
- 10.1.8. Europe Lung Cancer Therapeutics Market Dynamics – Trends

11. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

- 11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
- 11.1.2. Chemotherapy
 - 11.1.2.1. Taxol
 - 11.1.2.2. Navelbine

- 11.1.2.3. Alimta
- 11.1.2.4. Cisplatin
- 11.1.2.5. Camptosar
- 11.1.2.6. Others
- 11.1.3. Targeted therapy
 - 11.1.3.1. Gilotrif
 - 11.1.3.2. Tarceva
 - 11.1.3.3. Avastin
 - 11.1.3.4. Iressa
 - 11.1.3.5. Others
- 11.1.4. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 11.1.4.1. Small cell lung cancer
 - 11.1.4.2. Non-small cell lung cancer
 - 11.1.4.3. Large carcinoid tumor
- 11.1.5. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 11.1.5.1. Hospitals
 - 11.1.5.2. Oncology Clinics
 - 11.1.5.3. Ambulatory Surgical Centers
- 11.1.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 11.1.6.1. Japan
 - 11.1.6.2. China
 - 11.1.6.3. India
 - 11.1.6.4. ASEAN
 - 11.1.6.5. Australia & New Zealand
 - 11.1.6.6. Rest of Asia-Pacific
- 11.1.7. Asia-Pacific Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
- 11.1.8. Europe Lung Cancer Therapeutics Market Dynamics – Trends

12. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

- 12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
- 12.1.2. Chemotherapy

- 12.1.2.1. Taxol
- 12.1.2.2. Navelbine
- 12.1.2.3. Alimta
- 12.1.2.4. Cisplatin
- 12.1.2.5. Camptosar
- 12.1.2.6. Others
- 12.1.3. Targeted therapy
 - 12.1.3.1. Gilotrif
 - 12.1.3.2. Tarceva
 - 12.1.3.3. Avastin
 - 12.1.3.4. Iressa
 - 12.1.3.5. Others
- 12.1.4. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 12.1.4.1. Small cell lung cancer
 - 12.1.4.2. Non-small cell lung cancer
 - 12.1.4.3. Large carcinoid tumor
- 12.1.5. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 12.1.5.1. Hospitals
 - 12.1.5.2. Oncology Clinics
 - 12.1.5.3. Ambulatory Surgical Centers
- 12.1.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 12.1.6.1. Brazil
 - 12.1.6.2. Mexico
 - 12.1.6.3. Argentina
 - 12.1.6.4. Venezuela
 - 12.1.6.5. Rest of Latin America
- 12.1.7. Latin America Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
- 12.1.8. Latin America Lung Cancer Therapeutics Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA LUNG CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

- 13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
- 13.1.2. Chemotherapy

- 13.1.2.1. Taxol
- 13.1.2.2. Navelbine
- 13.1.2.3. Alimta
- 13.1.2.4. Cisplatin
- 13.1.2.5. Camptosar
- 13.1.2.6. Others
- 13.1.3. Targeted therapy
 - 13.1.3.1. Gilotrif
 - 13.1.3.2. Tarceva
 - 13.1.3.3. Avastin
 - 13.1.3.4. Iressa
 - 13.1.3.5. Others
- 13.1.4. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 13.1.4.1. Small cell lung cancer
 - 13.1.4.2. Non-small cell lung cancer
 - 13.1.4.3. Large carcinoid tumor
- 13.1.5. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 13.1.5.1. Hospitals
 - 13.1.5.2. Oncology Clinics
 - 13.1.5.3. Ambulatory Surgical Centers
- 13.1.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 13.1.6.1. Gulf Cooperation Council (GCC) Countries
 - 13.1.6.2. Israel
 - 13.1.6.3. South Africa
 - 13.1.6.4. Rest of MEA
- 13.1.7. MEA Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
- 13.1.8. MEA Lung Cancer Therapeutics Market Dynamics – Trends

14. COMPETITION LANDSCAPE

- 14.1. Strategic Dashboard of Top Market Players
- 14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
 - 14.2.1. AstraZeneca Plc. (UK)
 - 14.2.2. Merck & Co., Inc. (U.S.)

- 14.2.3. Pfizer, Inc. (U.S.)
- 14.2.4. Novartis AG (Switzerland)
- 14.2.5. Boehringer Ingelheim International GmbH (Germany)
- 14.2.6. Takeda Pharmaceutical Company Limited (Japan)
- 14.2.7. Abbvie, Inc (U.S.)
- 14.2.8. Vision Gate, Inc (U.S)
- 14.2.9. Asterias Biotherapeutics (Biotime) (U.S.)
- 14.2.10. GlaxoSmithKline Plc (U.K.)
- 14.2.11. F. Hoffmann La Roche (Switzerland)
- 14.2.12. Eli Lilly and Company (U.S.)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONY

I would like to order

Product name: Lung Cancer Therapeutics Market, 2012 to 2023

Product link: <https://marketpublishers.com/r/L541E0FA3CDEN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L541E0FA3CDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970